Farhan Javaid
Family Medicine · London, KYNPI 1417966425
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 430 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,717 and has fallen 55.3% since, to $768 in 2025. Among family medicine clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 430 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$728
- Lilly USA, LLC$654
- Pfizer$427
- Novartis$386
- Amgen$359
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,392100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 85 | $1,172 |
| AbbVie(2 entities) | 43 | $728 |
| Lilly USA, LLC | 51 | $654 |
| Pfizer | 37 | $427 |
| Novartis | 22 | $386 |
| Amgen | 25 | $359 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $341 |
| Amarin Pharma, Inc. | 20 | $270 |
| Bayer | 15 | $250 |
| Johnson & Johnson | 12 | $192 |
| Merck | 18 | $191 |
| Abbott | 10 | $189 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $150 |
| AstraZeneca | 5 | $146 |
| Intuitive Surgical | 1 | $125 |
| Astellas Pharma US Inc | 6 | $84 |
| Insulet Corporation | 3 | $76 |
| GSK | 5 | $74 |
| Radius Health, Inc. | 4 | $59 |
| Boehringer Ingelheim | 4 | $52 |
| Genentech USA, Inc. | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 3 | $34 |
| Antares Pharma, Inc. | 1 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Madrigal Pharmaceuticals | 1 | $29 |
| Seqirus USA Inc | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 2 | $24 |
| Valinor Pharma, LLC | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
| Pacira Therapeutics, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Sanofi | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,401 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $142,904 |
| JardianceEmpagliflozin | 150 | $136,167 |
| MounjaroTirzepatide | 86 | $91,713 |
| EliquisApixaban | 63 | $48,383 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $46,840 |
| JanuviaSitagliptin Phosphate | 32 | $33,765 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $31,529 |
| TrulicityDulaglutide | 28 | $30,231 |
| LinzessLinaclotide | 30 | $28,121 |
| Repatha SureclickEvolocumab | 39 | $24,264 |
| TradjentaLinagliptin | 27 | $23,779 |
| FarxigaDapagliflozin Propanediol | 25 | $14,632 |
| VascepaIcosapent Ethyl | 27 | $14,454 |
| WegovySemaglutide | 11 | $13,952 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $11,435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $52 | $159,947177 claims |
| Novo NordiskOzempic, Wegovy | $1,172 | $156,856144 claims |
| Lilly USA, LLCMounjaro, Trulicity | $654 | $121,944114 claims |
| PfizerEliquis | $427 | $48,38363 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $74 | $41,92171 claims |
| MerckJanuvia | $191 | $33,76532 claims |
| AbbVieLinzess, Synthroid | $728 | $32,72395 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $146 | $29,60756 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in London
- Jackie MaxeyLondon$12K
- Christopher RhyneLouisville$933K
- John RichardLexington$226K
- James TurnboPaducah$124K
- Edward SchumannFlorence$79K
- Ronald KoffNew Castle$71K
- Suraj GathaniLouisville$69K
- Bradley GrayFlorence$51K
- Jackie KazeeAshland$45K
- Mandy WhittLouisville$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.